Results 121 to 130 of about 173,196 (293)

Pseudo-outbreak of Mycobacterium gordonae in a teaching hospital: importance of strictly following decontamination procedures and emerging issues concerning sterilization [PDF]

, 2016
Aim of this study was to investigate a pseudo-outbreak of Mycobacterium gordonae analyzing isolates detected from clinical and environmental samples.
Alessia Cottarelli, Claudio M Mastroianni, Daniela M Cirillo, Fabio Mengoni, Lanfranco Fattorini, Laura Scorzolini, Lucia Marinelli, Maria De Giusti, MDPhD Laura Scorzolini, Rossella Baldan, Vincenzo Vullo   +10 more
core  

Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study

International Journal of Cancer, EarlyView.
The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang, Pingping Song, Yong Ge, Haitang Yang, Shuyuan Li, Ran Ma, Tianyue Ma, Shoujie Feng, Cheng Zhang, Teng Sun, Feng Yao, Jun Yi, Hao Zhang   +12 more
wiley   +1 more source

A Systematic Review of Cases of Meningitis in the Absence of Cerebrospinal Fluid Pleocytosis on Lumbar Puncture [PDF]

, 2019
Background: Definitive diagnosis of meningitis is made by analysis of cerebrospinal fluid (CSF) culture or polymerase chain reaction (PCR) obtained from a lumbar puncture (LP), which may take days.
Pettigrew, Alexis, Troendle, Michelle
core   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Pneumothorax and Pneumomediastinum in a Sputum Positive Tuberculosis Patient: The Continuous Diaphragm Sign [PDF]

, 2012
Secondary pneumothorax is a very common medical emergency. At times it is associated with pneumomediastinum, which could be fatal at times if not identified.
Bhatia, V, Jhobta, A, Mokta, JK, Panda, P, Sharma, S, Sood, RG   +5 more
core   +1 more source

Pleural Diseases

Seminars in Respiratory and Critical Care Medicine, 2019
Puchalski, J, Rahman, N
openaire   +2 more sources

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK's Haematological Malignancy Research Network

International Journal of Cancer, EarlyView.
Although tyrosine kinase inhibitors (TKIs) improve chronic myeloid leukemia (CML) outcome, long‐term effects remain unclear, particularly in real‐world settings. Here, the authors examined morbidity and mortality in CML patients treated with TKIs between 2009 and 2019 in the United Kingdom.
Eleanor Kane, Alexandra Smith, Debra Howell, Catherine Cargo, Kate Rothwell, Simone Green, Russell Patmore, Eve Roman   +7 more
wiley   +1 more source

Effectiveness and safety of iodopovidone in an experimental pleurodesis model

Clinics, 2013
OBJECTIVES: Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe.
Lisete R. Teixeira, Francisco S. Vargas, Juliana Puka, Milena M. P. Acencio, Leila Antonangelo, Ricardo M. Terra, Francisco M. Damico, Fabio G. Pitta, Evaldo Marchi   +8 more
doaj  

Pleural diseases and COVID-19: ubi fumus, ibi ignis. [PDF]

Eur Respir J, 2020
Porcel JM.
europepmc   +1 more source

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum‐resistant ovarian cancer: Phase I expansion results

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective In the dose‐escalation part of Study 101, which included multiple tumor types, objective responses were observed in 10 of 22 patients across multiple dose levels of farletuzumab ecteribulin (FZEC). We explored the safety/antitumor activity of FZEC in patients with platinum‐resistant ovarian cancer (PROC) from the Study 101 expansion ...
Kan Yonemori, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Yohei Otake, Wataru Yusa, Takuma Miura, Shin Nishio   +11 more
wiley   +1 more source